Food and Drug Administration (FDA)
NEWS
FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
Two weeks after acquiring two drugs from AstraZeneca in a $700 million deal, Germany-based Grünenthal flexed its M&A muscle again to acquire Averitas Pharma to extend its commercial footprint in the United States.
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
Viagra (sildenafil), Pfizer’s blockbuster drug for erectile dysfunction, is a classic example of how a drug developed for one thing can turn out to be successful for another.
Nestlé Increases Stake in Aimmune as Company Eyes Filing for FDA Approval of Peanut Allergy Medicine
As California-based Aimmune prepares to seek regulatory approval for its peanut allergy treatment, AR101, Nestlé Health Science has increased its financial stake in the food allergy prevention-focused company with another $98 million investment.
Texas-based Pain Therapeutics is urging the FDA to reconsider the Complete Response Letter it issued in August for the company’s opioid-treatment, Remoxy. Representatives from Pain Therapeutics will meet with the FDA on Jan. 31. 2019 to discuss the request, the company announced late Monday.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
JOBS
IN THE PRESS